ARU-1801 Gene Therapy for Sickle Cell Associated with Improved Clinical Outcomes

Article

Early results from the MOMENTUM study show that treated patients experienced fewer vaso-occlusive episodes and related hospital admissions.

gene therapy

Michael Grimley, MD

New data presented at the American Society of Gene & Cell Therapy (ASGCT) Virtual Meeting demonstrate the potential of ARU-1801 gene therapy for sickle cell disease (SCD).

A team led by Michael Grimley, MD, of Cincinnati Children’s Hospital Medical Center, reported on findings from the ongoing Phase 1/2 MOMENTUM study, which is evaluating the safety and efficacy of the new investigative gene therapy product among a sickle cell population. ARU-1801 consists of autologous CD34+ hematopoietic stem and progenitors (HSPCs) transduced with a lentiviral vector (LV) encoding a modified γ-globinG16D gene.

“Preliminary studies in SCD mice have suggested HbFG16D may have a more potent anti-sickling effect than wild-type HbF,” the team wrote. “As a high potency anti-sickling globin, HbFG16D is believed to allow ARU-1801 to be effective with reduced intensity conditioning (RIC), resulting in fewer toxicities and lower resource utilization than myeloablative approaches, expanding access to gene therapy to a broader group of SCD patients.”

Thus, according to long-term clinical data, ARU-1801 demonstrated a favorable safety profile, and no treatment-related adverse events were reported. These were observed across 3 treated patients with >9 months of follow-up data.

The investigators noted that RIC led to neutrophil engraftment within 7-9 days (median, 7) of infusion and platelet engraftment within 6-12 days (median, 7).

Under the initial manufacturing, Patient 1 demonstrated a steady vector copy number of 0.2, in addition to stable expression of 20% HbFG16D and 31% total anti-sickling globin (ASG). As noted by the investigators, ASG was composed of endogenous HbF, HbA2 and ARU-1801-derived HbFG16D.

Further, the patients showed 64% F-cells 2 years following gene therapy infusion.

Grimley’s team indicated that Patient 2 had a sub-therapeutic exposure to melphalan secondary to renal hyperfiltration and rapid clearance of melphalan — as such, this resulted in engraftment (VCN, 0.1) and thus lower HBFG16D.

Nevertheless, ASG expression was notably stable at 22%, as were F-cells at 36% 2 years post-infusion. This stability was due to sustained increases in endogenous HbF and HbA2.

Patient 3 had 10-month follow-up data (representative of the new manufacturing process) that showed a stable VCN of 0.7 with 41% ASG expression and 27% HbFG16D at month 10. Additionally, the patient had 92% F-reticulocytes at month 6, which indicates near pan-cellular expression of HbF.

All 3 patients had a median of 21 vaso-occlusive episodes in the 24 months prior to treatment with ARU-1801. They were hospitalized for a median of 6 of those episodes.

However, through 24 months post-infusion, patient 1 had a 93% reduction in the number of vaso-occlusive episodes, and patient 2 had an 85% reduction in the number of episodes. Through 10-months of follow-up, patient 3 experienced 0 vaso-occlusive episodes, thus demonstrating a 100% reduction.

Even more, the cumulative days spent in hospital from these episodes decreased from a median of 15 to a median of 0 days, showing an average of a 93.8% reduction.

“Treatment with ARU-1801 has resulted in remarkable improvement in clinical outcomes,” Grimely and team wrote.

“These results are an encouraging sign of the therapeutic benefit of ARU-1801 with RIC for patients with SCD,” they concluded.

The study, “Early Results from a Phase 1/2 Study of ARU-1801 Gene Therapy for Sickle Cell Disease (SCD): Safety and Efficacy of a Modified Gamma Globin Lentivirus Vector and Reduced Intensity Conditioning Transplant,” was presented at ASGCT 2021.

Related Videos
Hematopoietic Stem Cell Transplantation Improves Pediatric SCD Outcomes | Image Credit: Scott Graham/Unsplash
How Gene and Cell Therapy Is Developing in Dermatology
Joyce Teng, MD, PhD, discusses how therapeutic advances in fields like epidermolysis bullosa should progress treatment discourse in other rare dermatoses.
The Prospect of Pz-cel in RDEB Treatment, with Peter Marinkovich, MD
Comparing New Therapies for Dystrophic Epidermolysis Bullosa
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Dunia Hatabah, MD | Image Credit: HCPLive
Ricky Safer: What Clinicians Need to Know About PSC
Ryan T. Fischer, MD: Long-Term Odevixibat Benefit for Alagille Syndrome
Saeed Mohammad, MD: IBAT Inhibitors for Cholestatic Disease
© 2024 MJH Life Sciences

All rights reserved.